Notify me when Third Rock Ventures IV, L.P. files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| MAZE | Maze Therapeutics, Inc. | Common Stock, $0.001 par value per share | 13.9% | $53.4M | 6.07M | Third Rock Ventures IV, L.P. | Jan 31, 2025 | ||
| TNGX | Tango Therapeutics, Inc. | Common Stock | 5.85% | $62.8M | -$12M | 7.87M | -16% | Third Rock Ventures IV, L.P. | Nov 19, 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Date Filed |
|---|